Doxycycline and tigecycline: Two friendly drugs with a low association with Clostridium difficile infection

Antibiotics

Volumn 4, Issue 2, 2015, Pages 216-229

  Hung, Yuan Pin ^a,b,c   Lee, Jen Chieh ^b   Lin, Hsiao Ju ^a,b,c   Liu, Hsiao Chieh ^a,d   Wu, Yi Hui ^e   Tsai, Pei Jane ^d   Ko, Wen Chien ^b,d  

^a Tainan Hospital   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e E DA HOSPITAL   (Taiwan)

Author keywords

Clostridium difficile; Doxycycline; Tigecycline

Indexed keywords

CEPHALOSPORIN; CXCL9 CHEMOKINE; DOXYCYCLINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; RIFAXIMIN; TIGECYCLINE; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTEROIDETES; CELL PROLIFERATION; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE PREDISPOSITION; DRUG EXPOSURE; HUMAN; INTESTINE FLORA; MYCOPLASMA PNEUMONIA; OUTCOME ASSESSMENT; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; REVIEW;

CLOSTRIDIUM DIFFICILE; NEGIBACTERIA; POSIBACTERIA;

EID: 85014093939     PISSN: None     EISSN: 20796382     Source Type: Journal    
DOI: 10.3390/antibiotics4020216     Document Type: Review

References (74)

1. Bunnapradist, S.; Neri, L.; Wong, W.; Lentine, K.L.; Burroughs, T.E.; Pinsky, B.W.; Takemoto, S.K.; Schnitzler, M.A. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am.J.Kidney Dis.2008, 51, 478-486.
2. Roddie, C.; Paul, J.P.; Benjamin, R.; Gallimore, C.I.; Xerry, J.; Gray, J.J.; Peggs, K.S.; Morris, E.C.; Thomson, K.J.; Ward, K.N. Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: A previously unrecognized cause of morbidity. Clin.Infect.Dis.2009, 49, 1061-1068.
3. Polage, C.R.; Solnick, J.V.; Cohen, S.H. Nosocomial diarrhea: Evaluation and treatment of causes other than Clostridium difficile. Clin.Infect.Dis.2012, 55, 982-989.
4. Kelly, C.P.; LaMont, J.T.Clostridium difficile-More difficult than ever. N.Engl.J.Med.2008, 359, 1932-1940.
5. Kuijper, E.J.; van Dissel, J.T.; Wilcox, M.H. Clostridium difficile: Changing epidemiology and new treatment options. Curr.Opin.Infect.Dis.2007, 20, 376-383.
6. Loo, V.G.; Poirier, L.; Miller, M.A.; Oughton, M.; Libman, M.D.; Michaud, S.; Bourgault, A.M.; Nguyen, T.; Frenette, C.; Kelly, M.; et al.A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N.Engl.J.Med.2005, 353, 2442-2449.
7. Bartlett, J.G. Narrative review: The new epidemic of Clostridium difficile-associated enteric disease. Ann.Intern.Med.2006, 145, 758-764.
8. Lessa, F.C.; Mu, Y.; Bamberg, W.M.; Beldavs, Z.G.; Dumyati, G.K.; Dunn, J.R.; Farley, M.M.; Holzbauer, S.M.; Meek, J.I.; Phipps, E.C.; et al.Burden of Clostridium difficileinfection in the united states. N.Engl.J.Med.2015, 372, 825-834.
9. Chung, C.H.; Wu, C.J.; Lee, H.C.; Yan, J.J.; Chang, C.M.; Lee, N.Y.; Chen, P.L.; Lee, C.C.; Hung, Y.P.; Ko, W.C. Clostridium difficileinfection at a medical center in southern Taiwan: Incidence, clinical features and prognosis. J.Microbiol.Immunol.Infect.2010, 43, 119-125.
10. Hung, Y.P.; Lin, H.J.; Wu, T.C.; Liu, H.C.; Lee, J.C.; Lee, C.I.; Wu, Y.H.; Wan, L.; Tsai, P.J.; Ko, W.C. Risk factors of fecal toxigenic or non-toxigenic Clostridium difficilecolonization: Impact of toll-like receptor polymorphisms and prior antibiotic exposure. PLoS ONE2013, 8, e69577.
11. Riggs, M.M.; Sethi, A.K.; Zabarsky, T.F.; Eckstein, E.C.; Jump, R.L.; Donskey, C.J. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficilestrains among long-term care facility residents. Clin.Infect.Dis.2007, 45, 992-998.
12. Ryan, J.; Murphy, C.; Twomey, C.; Paul Ross, R.; Rea, M.C.; MacSharry, J.; Sheil, B.; Shanahan, F. Asymptomatic carriage of Clostridium difficilein an Irish continuing care institution for the elderly: Prevalence and characteristics. Ir.J.Med.Sci.2010, 179, 245-250.
13. Ubeda, C.; Taur, Y.; Jenq, R.R.; Equinda, M.J.; Son, T.; Samstein, M.; Viale, A.; Socci, N.D.; van den Brink, M.R.; Kamboj, M.; et al.Vancomycin-resistant enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J.Clin.Investig.2010, 120, 4332-4341.
14. Hung, Y.P.; Tsai, P.J.; Hung, K.H.; Liu, H.C.; Lee, C.I.; Lin, H.J.; Wu, Y.H.; Wu, J.J.; Ko, W.C. Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan. PLoS ONE2012, 7, e42415.
15. Britton, R.A.; Young, V.B. Interaction between the intestinal microbiota and host in Clostridium difficilecolonization resistance. Trends Microbiol.2012, 20, 313-319.
16. Vesteinsdottir, I.; Gudlaugsdottir,S.; Einarsdottir, R.; Kalaitzakis, E.; Sigurdardottir, O.; Bjornsson, E.S.Riskfactors for Clostridium difficiletoxin-positive diarrhea: A population-based prospective case-control study. Eur.J.Clin.Microbiol.Infect.Dis.2012, 31, 2601-2610.
17. Stevens, V.; Dumyati, G.; Fine, L.S.; Fisher, S.G.; van Wijngaarden, E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin.Infect.Dis.2011, 53, 42-48.
18. McFarland, L.V.; Clarridge, J.E.; Beneda, H.W.; Raugi, G.J. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a veterans administration health care system. Clin.Infect.Dis.2007, 45, 1141-1151.
19. McCusker, M.E.; Harris, A.D.; Perencevich, E.; Roghmann, M.C. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg.Infect.Dis.2003, 9, 730-733.
20. Delaney, J.A.; Dial, S.; Barkun, A.; Suissa, S. Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg.Infect.Dis.2007, 13, 761-763.
21. Wilcox, M.H.; Freeman, J.; Fawley, W.; MacKinlay, S.; Brown, A.; Donaldson, K.; Corrado, O. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficilediarrhoea. J.Antimicrob.Chemother.2004, 54, 168-172.
22. Settle, C.D.; Wilcox, M.H.; Fawley, W.N.; Corrado, O.J.; Hawkey, P.M. Prospective study of the risk of Clostridium difficilediarrhoeain elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment.Pharmacol.Ther.1998, 12, 1217-1223.
23. Alston, W.K.; Ahern, J.W. Increase in the rate of nosocomial Clostridium difficile-associated diarrhoeaduring shortages of piperacillin-tazobactam and piperacillin. J.Antimicrob.Chemother.2004, 53, 549-550.
24. Pultz, N.J.; Donskey, C.J. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficilein the cecal contents of mice. Antimicrob.Agents Chemother.2005, 49, 3529-3532.
25. Mendez, M.N.; Gibbs, L.; Jacobs, R.A.; McCulloch, C.E.; Winston, L.; Guglielmo, B.J. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistantenterococci and Clostridium difficileinfections. Pharmacotherapy2006, 26, 61-67.
26. Rodriguez, S.; Hernandez, M.B.; Tarchini, G.; Zaleski, M.; Vatanchi, M.; Cardona, L.; Castro-Pavia, F.;Schneider, A. Risk of Clostridium difficileinfection in hospitalized patients receiving metronidazole for a non-c difficileinfection. Clin.Gastroenterol.Hepatol.2014, 12, 1856-1861.
27. Hebert, C.; Du, H.; Peterson, L.R.; Robicsek, A. Electronic health record-based detection of risk factors for Clostridium difficileinfection relapse. Infect.Control Hosp.Epidemiol.2013, 34, 407-414.
28. Archimandritis, A.; Souyioultzis, S.; Katsorida, M.; Tzivras, M. Clostridium difficilecolitis associated with a "triple" regimen, containing clarithromycin and metronidazole, to eradicate helicobacter pylori. J.Intern.Med.1998, 243, 251-253.
29. Rashid, M.U.; Dalhoff, A.; Weintraub, A.; Nord, C.E. In vitroactivity of mcb3681 against Clostridium difficile strains. Anaerobe2014, 28, 216-219.
30. Rashid, M.U.; Lozano, H.M.; Weintraub, A.; Nord, C.E. In vitroactivity of cadazolid against Clostridium difficilestrains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe2013, 20, 32-35.
31. Barbut, F.; Mastrantonio, P.; Delmee, M.; Brazier, J.; Kuijper, E.; Poxton, I. Prospective study of Clostridium difficileinfections in Europe with phenotypic and genotypic characterisation of the isolates. Clin.Microbiol.Infect.2007, 13, 1048-1057.
32. Huang, H.; Fang, H.; Weintraub, A.; Nord, C.E. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficilefrom Shanghai and Stockholm. Clin.Microbiol.Infect.2009, 15, 1170-1173.
33. Kouassi, K.A.; Dadie, A.T.; N'Guessan, K.F.; Dje, K.M.; Loukou, Y.G. Clostridium perfringensand Clostridium difficilein cooked beef sold in cote d'ivoire and their antimicrobial susceptibility. Anaerobe2014, 28, 90-94.
34. Simango, C.; Mwakurudza, S. Clostridium difficilein broiler chickens sold at market places in Zimbabwe and their antimicrobial susceptibility. Int.J.Food Microbiol.2008, 124, 268-270.
35. Simango, C. Prevalence of Clostridium difficile in the environment in a rural community in Zimbabwe. Trans.R.Soc.Trop.Med.Hyg.2006, 100, 1146-1150.
36. Alcala, L.; Martin, A.; Marin, M.; Sanchez-Somolinos, M.; Catalan, P.; Pelaez, T.; Bouza, E. The undiagnosed cases of Clostridium difficileinfection in a whole nation: Where is the problem? Clin.Microbiol.Infect.2012, 18, E204-E213.
37. Schmidt, C.; Loffler, B.; Ackermann, G. Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile. Diagn.Microbiol.Infect.Dis.2007, 59, 1-5.
38. Bishara, J.; Bloch, Y.; Garty, M.; Behor, J.; Samra, Z. Antimicrobial resistance of Clostridium difficileisolates in a tertiary medical center, israel. Diagn.Microbiol.Infect.Dis.2006, 54, 141-144.
39. Hojer, H.; Wetterfors, J. Concentration of doxycycline in bowel tissue and postoperative infections. Scand.J.Infect.Dis.Suppl.1976, 9, 100-105.
40. Baxter, R.; Ray, G.T.; Fireman, B.H. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect.Control Hosp.Epidemiol.2008, 29, 44-50.
41. Doernberg, S.B.; Winston, L.G.; Deck, D.H.; Chambers, H.F. Does doxycycline protect against development of Clostridium difficileinfection? Clin.Infect.Dis.2012, 55, 615-620.
42. Turner, R.B.; Smith, C.B.; Martello, J.L.; Slain, D. Role of doxycycline in Clostridiumdifficile infection acquisition. Ann.Pharmacother.2014, 48, 772-776.
43. Golledge, C.L.; Riley, T.V. Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis. Lancet 1995, 345, 1377-1378.
44. Dong, D.; Zhang, L.; Chen, X.; Jiang, C.; Yu,B.; Wang, X.; Peng, Y. Antimicrobial susceptibility and resistance mechanisms of clinical Clostridium difficilefrom a Chinese tertiary hospital. Int.J.Antimicrob.Agents2013, 41, 80-84.
45. Huang, H.; Weintraub, A.; Fang, H.; Wu, S.; Zhang, Y.; Nord, C.E. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficilestrains. Anaerobe2010, 16, 633-635.
46. Huang, H.; Wu, S.; Wang, M.; Zhang, Y.; Fang, H.; Palmgren, A.C.; Weintraub, A.; Nord, C.E.Clostridium difficileinfections in a shanghai hospital: Antimicrobial resistance, toxin profiles and ribotypes. Int.J.Antimicrob.Agents2009, 33, 339-342.
47. Lin, Y.C.; Huang, Y.T.; Tsai, P.J.; Lee, T.F.; Lee, N.Y.; Liao, C.H.; Lin, S.Y.; Ko, W.C.; Hsueh, P.R. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficilein Taiwan. Antimicrob Agents Chemother 2011, 55, 1701-1705.
48. Hecht, D.W.; Galang, M.A.; Sambol, S.P.; Osmolski, J.R.; Johnson, S.; Gerding, D.N. In vitroactivities of 15 antimicrobial agents against 110 toxigenic Clostridium difficileclinical isolates collected from 1983 to 2004. Antimicrob.Agents Chemother.2007, 51, 2716-2719.
49. Edlund, C.; Sabouri, S.; Nord, C.E. Comparativein vitroactivity of bay 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur.J.Clin.Microbiol.Infect.Dis.1998, 17, 193-195.
50. Hawser, S.P. Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int.J.Antimicrob.Agents2010, 35, 97-98.
51. Lachowicz, D.; Pituch, H.; Obuch-Woszczatynski, P. Antimicrobial susceptibility patterns of Clostridium difficilestrains belonging to different polymerase chain reaction ribotypesisolated in Poland in 2012. Anaerobe2015, 31, 37-41.
52. Bassis, C.M.; Theriot, C.M.; Young, V.B. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficileinfection. Antimicrob.Agents Chemother.2014, 58, 2767-2774.
53. Baines, S.D.; Saxton, K.; Freeman, J.; Wilcox, M.H. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficilestrains in a human gut model. J.Antimicrob.Chemother.2006, 58, 1062-1065.
54. Jump, R.L.; Li, Y.; Pultz, M.J.; Kypriotakis, G.; Donskey, C.J. Tigecycline exhibits inhibitory activity against Clostridium difficilein the colon of mice and does not promote growth or toxin production. Antimicrob.Agents Chemother.2011, 55, 546-549.
55. Aldape, M.J.; Heeney, D.D.; Bryant, A.E.; Stevens, D.L. Tigecycline suppresses toxin a and b production and sporulation in Clostridium difficile. J.Antimicrob.Chemother.2015, 70, 153-159.
56. Theriot, C.M.; Schumacher, C.A.; Bassis, C.M.; Seekatz, A.M.;Young, V.B. Effects of tigecycline and vancomycin administration on establishedClostridium difficileinfection. Antimicrob.Agents Chemother.2015, 59, 1596-1604.
57. Larson, K.C.; Belliveau, P.P.; Spooner, L.M. Tigecycline for the treatment of severe Clostridium difficileinfection. Ann.Pharmacother.2011, 45, 1005-1010.
58. Cheong, E.Y.; Gottlieb, T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficilecolitis. Med.J.Aust.2011, 194, 374-375.
59. DuPont, H.L. The search for effective treatment of Clostridium difficileinfection. N.Engl.J.Med.2011, 364, 473-475.
60. Gerding, D.N.; Muto, C.A.; Owens, R.C., Jr. Treatment of Clostridium difficileinfection. Clin.Infect.Dis.2008, 46, S32-S42.
61. Dunston, C.R.; Griffiths, H.R.; Lambert, P.A.; Staddon, S.; Vernallis, A.B. Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics2011, 11, 42-51.
62. Saliba, R.; Paasch, L.; El Solh, A. Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines. Immunopharmacol.Immunotoxicol.2009, 31, 583-588.
63. Salvatore, C.M.; Techasaensiri, C.; Tagliabue, C.; Katz, K.; Leos, N.; Gomez, A.M.; McCracken, G.H.; Hardy, R.D. Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniaepneumonia. Antimicrob.Agents Chemother.2009, 53, 1546-1551.
64. Yagnik, R.M.; Benzeroual, K.E. Tigecycline prevents lps-induced release of pro-inflammatory and apoptotic mediators in neuronal cells. Toxicol.In Vitro2013, 27, 686-693.
65. Zar, F.A.; Bakkanagari, S.R.; Moorthi, K.M.; Davis, M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin.Infect.Dis.2007, 45, 302-307.
66. Gerding, D.N. Is there a relationship between vancomycin-resistant enterococcal infection andClostridium difficile infection? Clin.Infect.Dis.1997, 25, S206-S210.
67. Bagdasarian, N.; Rao, K.; Malani, P.N. Diagnosis and treatment of Clostridium difficilein adults: A systematic review. JAMA2015, 313, 398-408.
68. Herpers, B.L.; Vlaminckx, B.; Burkhardt, O.; Blom, H.; Biemond-Moeniralam, H.S.; Hornef, M.; Welte, T.; Kuijper, E.J. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficileinfection. Clin.Infect.Dis.2009, 48, 1732-1735.
69. Lu, C.L.; Liu, C.Y.; Liao, C.H.; Huang, Y.T.; Wang, H.P.; Hsueh, P.R. Severe and refractory Clostridium difficileinfection successfully treated with tigecycline and metronidazole. Int.J.Antimicrob.Agents2010, 35, 311-312.
70. Lao, D., 2nd; Chiang, T.; Gomez, E. RefractoryClostridium difficileinfection successfully treated with tigecycline, rifaximin, and vancomycin. Case Rep.Med.2012, 2012, e702910.
71. El-Herte, R.I.; Baban, T.A.; Kanj, S.S. Recurrent refractory Clostridium difficilecolitis treated successfully with rifaximin and tigecycline: A case report and review of the literature. Scand.J.Infect.Dis.2012, 44, 228-230.
72. Britt, N.S.; Steed, M.E.; Potter, E.M.; Clough, L.A. Tigecycline for the treatment of severe and severe complicated Clostridium difficileinfection. Infect.Dis.Ther.2014,3, 321-331.
73. Thomas, A.; Khan, F.; Uddin, N.; Wallace, M.R. Tigecycline for severe Clostridium difficileinfection. Int.J.Infect.Dis.2014, 26, 171-172.
74. Kopterides, P.; Papageorgiou, C.; Antoniadou, A.; Papadomichelakis, E.; Tsangaris, I.; Dimopoulou, I.; Armaganidis, A. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth.Intensive Care2010, 38, 755-758.